LinkedIn

Dr. Fox was part of the team that performed the first-in-human studies of genetically-modified cells (NCI) and was an investigator on the first clinical trial to genetically modify tumors in patients (U of M), the first gene therapy trial for HIV/AIDS (U of M) and the first trial of gene-modified tumor vaccines in Oregon. Dr. Fox’s research efforts are divided between preclinical animal models and the development, performance and monitoring of immunotherapy trials for patients with cancer. His research efforts have been supported by the NCI / NIH, the Department of Defense, biotechnology and pharmaceutical companies and philanthropic sources.

A founding member of the Tumor Vaccine and Cell Therapy Working Group (TVACT), Dr. Fox has coordinated their international meetings for the past 17 years. He is currently the chair of the World Immunotherapy Council (WIC), and a past President and member of the Executive Council of the Society for Immunotherapy of Cancer (SITC). He has served as a member of review committees for the NIH, FDA, Universities, philanthropic and governmental organizations in the USA, Europe and Asia, is on the editorial boards of six scientific journals, lectures widely, consults for the biotechnology/pharma sector and is an internationally recognized expert on cancer immunotherapy. Dr. Fox served as a member of the Board of Directors, NeoPharm Inc. (www.insysrx.com), and is a co-founder and managing-member of UbiVac, an R&D biotechnology company developing innovative new strategies to treat cancer. In 2011 he co-founded UbiVac-CMV to develop disabled-CMV vector-based vaccines.

Specialties: Tumor Immunology, Cancer Immunotherapy, Translational Research (Bench-to-bedside), Biotechnology, Academic-Biotech partnerships, Corporate Director.